Science Explorer Back to mapMap
Discussion
Researcher · BioInvent (Sweden) · Sweden

Björn Frendéus

Björn Frendéus publishes mostly in Immunology, Radiology, Nuclear Medicine and Imaging and Oncology, on topics such as Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research and Chronic Lymphocytic Leukemia Research.

ORCID 0000-0003-3177-8686 OpenAlex
World rank
#492,626
of 7,710,434 ranked researchers
Rank in Sweden
#5,989
of 71,437
Works
120
Citations
3.7k
Citations per work
31.0
h-index
31
i10-index 42Top 14% in Immunology
Björn Frendéus

What does Björn Frendéus research?

Björn Frendéus's work is mostly in Medicine (43%), Immunology and Microbiology (25%), Biochemistry, Genetics and Molecular Biology (12%).

Health Sciences: 51 works · 42.7% of their workMedicine: 51 works · 42.7% of their workRadiology, Nuclear Medicine and Imaging: 24 works · 19.9% of their workOncology: 17 works · 14.0% of their workGenetics: 7 works · 5.5% of their workEpidemiology: 4 works · 3.3% of their workLife Sciences: 44 works · 36.9% of their workImmunology and Microbiology: 30 works · 24.7% of their workImmunology: 30 works · 24.7% of their workBiochemistry, Genetics and Molecular Biology: 15 works · 12.2% of their workMolecular Biology: 15 works · 12.2% of their workEverything else: 24 works · 20.4% of their workTHEIR WORKBjörn Frendéus120works
Life Sciences37%Health Sciences43%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine5142.7%
    1. Immunology and Microbiology3024.7%
    2. Biochemistry, Genetics and Molecular Biology1512.2%
  3. Everything else2420.4%
  1. 1Immunology25% of their works
  2. 2Radiology, Nuclear Medicine and Imaging20% of their works
  3. 3Oncology14% of their works
  4. 4Molecular Biology12% of their works
  5. 5Genetics6% of their works
  6. 6Epidemiology3% of their works

Research topics

Which keywords describe Björn Frendéus's research?

The keywords of their largest research topics: Glycosylation, Fc Receptors, Therapeutic Antibodies, Cancer, Glycans, Chronic Lymphocytic Leukemia, Genomic Aberrations and Foxp3.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Glycosylation672 topics
  2. Fc Receptors491 topic
  3. Therapeutic Antibodies491 topic
  4. Cancer181 topic
  5. Glycans181 topic
  6. Chronic Lymphocytic Leukemia151 topic
  7. Genomic Aberrations151 topic
  8. Foxp3131 topic
  9. Immune Checkpoint Blockade131 topic
  10. PD-1 and PD-L1131 topic
  11. Pattern Recognition Receptors131 topic
  12. TGF-ß131 topic
  13. Toll-like Receptors131 topic
  14. Dendritic Cells121 topic
  15. Immunity121 topic
  16. Breast Cancer101 topic
  17. HER2101 topic

Where does Björn Frendéus work?

Björn Frendéus's main affiliation in the publication record is BioInvent (Sweden), Sweden.

How many publications and citations does Björn Frendéus have?

OpenAlex counts 120 works and 3,721 citations for Björn Frendéus, an h-index of 31, ranking #492,626 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Björn Frendéus. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.